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Acute hemolytic transfusion
reaction caused by anti-Coa
R.B. COVIN, K.S. EVANS, R. OLSHOCK, AND H.W. THOMPSON
Coa is a high-frequency blood group antigen in the Colton blood
group system expressed on red blood cells (RBCs) of
approximately 99.8 percent of random persons. Anti-Coa has been
reported to cause delayed hemolytic transfusion reactions,
hemolytic disease of the newborn, and accelerated clearance of
RBCs in vivo. Acute hemolytic transfusion reactions (AHTRs) have
not previously been reported. A 58-year-old man was hospitalized
for vascular surgery. Initial blood bank evaluation revealed anti-Fya.
The patient received six units of RBCs during his initial
hospitalization and developed anti-E. A subsequent sample was sent
to the reference laboratory when all units of RBCs appeared
incompatible. Additional studies, including alloadsorptions, revealed
the presence of anti-E, anti-Fya, and an apparent warm autoantibody.
One unit of least-incompatible RBCs was transfused during surgery.
The patient had an increase in temperature. Hemoglobinuria and a
decrease in hematocrit were also noted. Due to the clinical
impression of an AHTR, the pre- and postreaction samples were re-
evaluated in the reference laboratory and demonstrated the
presence of anti-Coa in both. Based on clinical and laboratory
evaluation this patient appears to have had an AHTR due to anti-Coa.
This is the first known reported case of an AHTR caused by anti-Coa.
Immunohematology 2001;17:45–49.
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Coa is a high-frequency blood group antigen
expressed on red blood cells (RBCs) of 99.8 percent of
Caucasians and may be more frequent in other ethnic-
racial groups.1 The Colton protein has been identified
as aquaporin 1, a red cell water-selective transport
protein that regulates water homeostasis.2 The first
examples of anti-Coa were described by Heisto et al. in
1967.3 Anti-Coa has been reported to cause delayed
hemolytic transfusion reactions,4 hemolytic disease of
the newborn,5 and accelerated clearance of RBCs in an
in vivo survival study.6 Acute hemolytic transfusion
reactions (AHTRs) due to anti-Coa have not previously
been reported. The case presented here concerns a
patient who developed an apparent AHTR due to anti-
Coa. We believe that this case is the first reported case
of an AHTR caused by anti-Coa.
Case Report
A 58-year-old group A, D+ man with longstanding
venous insufficiency was admitted to the hospital on
February 18, 2000 for left leg valve transplantation. His
medical history was significant for a 38-year history of
pain, edema, and discomfort in his left lower extremity
due to venous insufficiency, ulcers, and thromboses.
He had received multiple red cell transfusions during
surgery for ulcer excisions followed by skin grafts,
multiple nerve blocks, and a sympathectomy. He had
a history of moderate-to-severe aortic stenosis and of
gastrointestinal bleeding in 1993. At that time he was
also noted to have anti-Fya. Medications on admission
included oxycodone, amitriptyline, zolpidem, and
warfarin. Admission hemoglobin was 11.9 g/dL.
Initial blood bank evaluation confirmed anti-Fya. The
patient’s RBC phenotype was reported as Fy (a–), Jk (a),
and S–. The patient underwent a left lower extremity
venous valve transplant on February 18, 2000. A
left deep venous thrombosis necessitating heparin
therapy complicated the patient’s postoperative course.
Subsequently, the patient developed left thigh
and popliteal hematomas that were evacuated on
February 28, 2000. During this phase of the patient’s
hospitalization, and prior to this second operation,
the patient received 6 units of RBCs. An anti-E was
detected for the first time. A type and crossmatch just
prior to the patient’s second surgery revealed no
compatible units and the specimen was sent to the
reference laboratory. Additional studies including
alloadsorptions revealed the presence of anti-E, -Fya, a
cold autoantibody, and an apparent warm autoantibody.
Further phenotyping revealed that the patients RBCs
also were E– and K–. Eight units of least-incompatible
RBCs were sent to the patient’s hospital. During the
second surgery, the patient was transfused with one of
the units and the other seven were returned. The
transfused unit was E–, Fy (a–), K–, and Jk (a–). In
the postanesthesia recovery unit, within 60 minutes
from the start of the transfusion, the patient was noted
to develop rigors, increased temperature, and
hemoglobinuria. The hematocrit was also noted to have
decreased. There was no clinical evidence of bleeding
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to account for the decline in hematocrit. Due to the
clinical impression of an AHTR, the pre- and immediate
postreaction samples were re-evaluated in the reference
laboratory. A panel of RBCs to test for the presence
of antibodies to high-frequency antigens demonstrated
anti-Coa. A posttransfusion sample revealed a new
anti-Jka. The patient’s RBCs were Co(a–) and Jk(a–).
Materials and Methods
Polyspecific anti-IgG, -C3d, murine monoclonal anti-
IgG (Gamma Biologicals, Houston, TX) and murine
monoclonal anti-C3b, C3d (Ortho-Clinical Diagnostics,
Raritan, NJ) were used for the direct antiglobulin
test (DAT). Testing was performed at immediate spin
and after a 10-minute incubation.
The following monoclonal reagents were used for
the initial reference laboratory RBC phenotyping:
anti-A, -B, -D, -C, -c, -E, and -e (Ortho); the following
indirect antiglobulin reagents were used: anti-K, -Fya,
-S (Ortho) and -Jka (Gamma). The patient’s ABO serum
grouping was performed using A
1
 and B cells (Ortho).
Initial panels used in the reference laboratory
investigation included select cells from Panocell 16
(Lot # 09280, Immucor, Norcross, Georgia) and Panel
One (Lot numbers 0222 and 0118, Gamma). Panels
were read at immediate spin, followed by the addition
of two drops of N-Hance (Gamma). Each tube was
incubated at 37°C for 10 minutes, followed by
centrifugation and reading. Each tube was washed x 4
with saline, two drops of anti-IgG (Gamma) were added,
followed by centrifugation and reading. Negative
antihuman globulin reactions were checked using
Coombs Control Cells (Ortho).
A cold autoantibody, one of the suspected antibodies,
interfered with the patient’s ABO serum grouping. The
test was repeated and resolved using two drops of the
patient’s serum plus A
1
 and B cells, and O cord cells. A
prewarmed panel was performed, using the same cells
as the original select cell panel. The following were
warmed separately at 37°C for 5 to 10 minutes: one
drop of each panel cell to be tested, enough N-Hance to
add two drops to each tube, and the patient’s serum.
Two drops of prewarmed serum and N-Hance were
added to each panel cell tube. All tubes were incu-
bated at 37°C for 10 minutes. All tubes were washed
x 4 with warm saline, followed by the addition of two
drops of anti-IgG (Gamma) to each tube.
An acid eluate was performed using Elu-Kit II
(Gamma). As a control, the last wash was tested against
two selectogen cells (Ortho). Polyethylene glycol (PEG)
adsorptions were performed to remove the apparent
warm autoantibody from the serum. Raw PeG (Sigma
Chemicals, St. Louis, MO) was obtained and prepared as
a reagent for use in our laboratory using the following
method: 20 grams of PEG dissolved into 100 mL of
phosphate-buffered saline. Three different donor’s cells
(Bonfils Blood Center, Denver, CO) lacking the following
antigens were used to perform the adsorptions:
• Donor 1 (O, D+) lacking E, c, Fya, Jkb, and K antigens
• Donor 2 (O, D+) lacking C, E, Fya, Fyb, Jkb, K, and
S antigens
• Donor 3 (O, D–) lacking E, Fya, Jka, K, and s antigens
The cells from the three donors were tightly packed,
with as much donor plasma as possible removed.
Equal volumes of packed adsorbing RBCs, PEG, and
patient’s serum were incubated at 37°C for 15 minutes.
Following centrifugation, the adsorbed serum was
harvested and tested against a select cell panel from the
initial panels used in the investigation.
Upon report of the suspected transfusion reaction,
the patient’s pretransfusion serum was tested with the
following cells: one Rh
null
 / Fy (a+), one Rh
null
 / Fy (a–),
three E– / Fy (a–), and one Co (a–). The pretransfusion
eluate was also tested against the Rh
null
/Fy (a–) cell.
The patient’s RBCs were further phenotyped for the
following antigens: Vel, Kpb, I, Coa, Lub, Yta, PP
1
Pk, Ge,
and LAN. A select cell panel was run using methods
already described, testing at least one cell that was
negative for each of the high-frequency antigens listed
above. Seven more Co(a–), E–, Fy (a–) RBCs were tested
with the patient’s serum. Six of these cells were Jk (a+).
All rare cells and antisera were obtained from either the
Serum, Cells, and Rare Fluids (SCARF) program or
Bonfils Blood Center donors.
Results
Pretransfusion antibody study
As the patient’s type and crossmatch prior to his
second surgery revealed no compatible units, the
specimen was sent to the reference laboratory for
further evaluation. This evaluation revealed an anti-E
reactive at 37°C with N-Hance and anti-Fya plus -E at the
antiglobulin test using anti-IgG. A cold autoantibody at
immediate spin (IS) and an apparent warm
autoantibody were also present. The serologic
evaluation is shown in Figure 1. All negative anti-
human globulin reactions showed agglutination with
check cells.
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An eluate showed a panagglutinin at IS. At the
antiglobulin test, anti-E plus a panagglutin was present
and the adsorbed serum contained only anti-E plus -Fya
(Fig. 1).
antigen. The results of this evaluation are shown in
Figure 2. An antibody to Coa by LISS IgG was identified.
All negative anti-human globulin reactions showed
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Temperature (C) 38.4 39.2




Hematocrit (%) 22.3 18.3
Creatinine (mg/dL) 1.1 1.8
Bilirubin (mg/dL) — 3.9
Urinalysis — hemoglobinuria
Blood bank evaluation
ABO and Rh A+ A+ A+
Serum normal icteric normal
DAT (IgG) +/– 1+w
Clerical check OK OK
*Acute hemolytic transfusion reaction
Fig. 1.Pretransfusion evaluation performed by reference laboratory. Antibodies identified included anti-E, anti-Fya, and “cold” and “warm” autoantibodies.
Transfusion reaction clinical, laboratory, and
serologic evaluation
Following transfusion of one of the units of RBCs, the
patient developed signs and symptoms suggestive of
an AHTR. The results of the hospital’s transfusion
reaction evaluation are shown in Table 1. The sample
was drawn within 3 hours from the time of the
suspected AHTR. Most notable were the laboratory
values and an increase in the strength of the DAT.
Identification of anti-Coa
Due to the AHTR, the reference laboratory re-
evaluated the patient’s pretransfusion sample in an
attempt to identify an antibody to a high-frequency
48 I M M U N O H E M A T O L O G Y ,   V O L U M E  1 7,  N U M B E R  2,  2 0 0 1
Fig. 2.Re-evaluation performed by reference laboratory on the pretransfusion sample following the report of an AHTR. Anti-Coa was identified. Patient’s
phenotype was Co (a–).
agglutination with check cells. Phenotyping of the
patient’s RBCs revealed the patient was Co (a–).
In further testing, Rh
null
 / Fy(a+) cells tested 2+
positive, whereas Rh
null
 / Fy (a–) cells tested ± and
antibodies to Vel, Kpb, I, Lub, Yta, PP
1
Pk, Ge, and LAN were
ruled out. A posttransfusion sample, in addition to anti-
Coa, -E, and -Fya, also revealed the presence of an anti-Jka.
Discussion
An AHTR is defined as the rapid destruction of RBCs
that occurs during or shortly after a blood transfusion
(< 24 hours). The most common cause of AHTR is
transfusion of ABO-incompatible RBCs with formation
of antigen-antibody complexes that induce activation of
the complement cascade and lead to intravascular
hemolysis. Most often, these antibodies are IgM and are
naturally acquired; however, antibodies may be IgG
and can be acquired due to a previous pregnancy or
blood transfusion. The clinical features of an AHTR are
variable and depend on the quantity of incompatible
RBCs transfused, the type of antibody and its antigen
specificity, the thermal amplitude of the antibody,
complement activation, and the clinical condition of the
patient. The most frequent presentation is fever (greater
than a 1°C rise in temperature) with or without chills.
Other signs and symptoms include hemoglobinemia,
hemoglobinuria, hypotension, chest pain, dyspnea,
flushing, oliguria or anuria, and disseminated
intravascular coagulation. Laboratory diagnosis usually
includes a decline in hematocrit, hemoglobinemia,
hemoglobinuria, and a positive DAT that may
show a mixed-field appearance. An unconjugated
hyperbilirubinemia, abnormal coagulation studies,
and worsening renal function may also be identified.7
Our patient developed an increased temperature
(although not greater than 1°C), a decrease in
hematocrit, hemoglobinuria, and increased strength of
the DAT consistent with the clinical impression of an
AHTR. Re-evaluation of the patient’s serum samples
identified an antibody to the high-frequency antigen Coa
and a new anti-Jka. Phenotyping of the patients RBCs
revealed the patient to be Co (a–). Because Co (a–), Jk
(a+) cells did not show agglutination during repeat
testing of the pretransfusion sample, we feel that it is
highly likely that the transfusion reaction was caused by
anti-Coa. In addition, the reaction was most consistent
with a preformed antibody and the anti-Jka was
identified only after the transfusion reaction. The only
Jk (a+) units that were transfused were given 1 month
prior to the reaction and this length of time is not
consistent with a delayed transfusion reaction. Our
patient did not receive any further transfusions during
his hospital stay so we cannot document an increase
in hematocrit and a lack of reaction to a transfusion of
Co(a–) RBCs.
The differential diagnosis for an AHTR includes
thermal destruction of RBCs by heating and cooling
devices, concomitant administration of drugs or
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nonisotonic fluids, bacterial contamination, or a
hemolytic condition within the recipient (e.g.,
autoimmune hemolytic anemia).7 In our patient, no
other causes for the AHTR were identified.
This case describes what we believe to be the first
reported case of an AHTR caused by anti-Coa. Previous
reports have implicated anti-Coa in delayed hemolytic
transfusion reactions4 and hemolytic disease of the
newborn.5 In addition, accelerated clearance of Co(a+)
RBCs has been identified in patients with anti-Coa
during in vivo survival studies.3,6 In their initial report,
Heisto et al.3 described a shortened T
50
 when Co(a+)
RBCs were injected into a patient with anti-Coa. These
findings were later confirmed by Kurtz et al.6 who
found a T
50
 of only 5 minutes in a 56-year-old G3P2
woman with a history of four previous transfusions. She
was identified as having anti-Coa and rapidly cleared
51Cr-labeled Co(a+) RBCs within 24 hours. The authors
suggested that Co(a–b+) RBCs be used for transfusion
in patients with anti-Coa. Although anti-Coa is most often
IgG, some of these antibodies have been shown to bind
complement and examples of IgM antibodies have been
reported.6 Even though Coa has not previously been
reported to cause an AHTR, Lee and Bennett8 reported
a case of a 74-year-old man who developed an AHTR
due to anti-Cob.
In our case, the anti-Coa was initially diagnosed as a
warm autoantibody (WAA) due to its reactivity with all
test cells. The differentiation between a WAA and a high-
frequency antigen can be difficult. Cash et al.9 reported
similar difficulty with a 60-year-old female who was
initially suspected to have a warm autoantibody.
After transfusion of two units of RBCs, she developed
a delayed hemolytic transfusion reaction. The antibody
was subsequently identified as anti-Ata.
We believe the clinical presentation and laboratory
evaluation is consistent with an AHTR due to anti-Coa.
AHTR DUE TO ANTI-COA
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